Cyltezo Is a Contender for First Interchangeable to Humira, Boehringer Ingelheim Says
April 29th 2021
ArticleThe results of Voltaire-X could persuade the FDA to authorize automatic substitution of the adalimumab biosimilar Cyltezo for its reference product (Humira), investigators believe.